<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36723656</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1660-9379</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>812</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Revue medicale suisse</Title><ISOAbbreviation>Rev Med Suisse</ISOAbbreviation></Journal><ArticleTitle>[Rheumatology : what's new in 2022].</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>242</EndPage><MedlinePgn>239-242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53738/REVMED.2023.19.812.239</ELocationID><Abstract><AbstractText>In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib compared to TNF-alpha inhibitors. Interesting data on the outcome of pregnancy in patients with spondylarthritis have also been published. New molecules and different treatment strategies have shown promising results in psoriatic arthritis and systemic lupus erythematosus. The utility of botulinum toxin A injections for Raynaud's phenomenon and the efficacy of transplantation of autologous adipose-derived regenerative cells for the treatment of hand dysfunctions have been questioned by 2 randomized controlled trials of patients with systemic sclerosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iudici</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de rhumatologie, D&#xe9;partement de m&#xe9;decine, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarou</LastName><ForeName>Ilias</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Service de rhumatologie, D&#xe9;partement de m&#xe9;decine, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Service de rhumatologie, D&#xe9;partement de m&#xe9;decine, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauper</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Service de rhumatologie, D&#xe9;partement de m&#xe9;decine, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Rhumatologie : ce qui a chang&#xe9; en 2022.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Rev Med Suisse</MedlineTA><NlmUniqueID>101219148</NlmUniqueID><ISSNLinking>1660-9379</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="Y">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019274" MajorTopicYN="Y">Botulinum Toxins, Type A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Cette ann&#xe9;e a vu un approfondissement des connaissances sur le traitement de la polyarthrite rhumato&#xef;de, avec la publication de r&#xe9;sultats d&#x2019;essais randomis&#xe9;s &#xe9;valuant une nouvelle mol&#xe9;cule ciblant l&#x2019;IL-6 et le profil de s&#xe9;curit&#xe9; du tofacitinib par rapport aux inhibiteurs du TNF-alpha. Des donn&#xe9;es int&#xe9;ressantes sur l&#x2019;issue de la grossesse chez les patientes atteintes de spondylarthrite ont &#xe9;galement &#xe9;t&#xe9; publi&#xe9;es. De nouvelles strat&#xe9;gies de traitement ont donn&#xe9; des r&#xe9;sultats prometteurs dans le rhumatisme psoriasique et le lupus &#xe9;ryth&#xe9;mateux syst&#xe9;mique. L&#x2019;utilit&#xe9; des injections de toxine botulique A pour le ph&#xe9;nom&#xe8;ne de Raynaud et l&#x2019;efficacit&#xe9; de la transplantation de cellules r&#xe9;g&#xe9;n&#xe9;ratrices adipeuses autologues pour le traitement de dysfonctions de la main ont &#xe9;t&#xe9; remises en question par deux &#xe9;tudes dans la scl&#xe9;rose syst&#xe9;mique.</AbstractText></OtherAbstract><CoiStatement>Les auteurs n&#x2019;ont d&#xe9;clar&#xe9; aucun conflit d&#x2019;int&#xe9;r&#xea;ts en relation avec cet article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36723656</ArticleId><ArticleId IdType="doi">10.53738/REVMED.2023.19.812.239</ArticleId><ArticleId IdType="pii">RMS0812-019</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>